PepExplainer: An explainable deep learning model for selection-based macrocyclic peptide bioactivity prediction and optimization.

Journal: European journal of medicinal chemistry
PMID:

Abstract

Macrocyclic peptides possess unique features, making them highly promising as a drug modality. However, evaluating their bioactivity through wet lab experiments is generally resource-intensive and time-consuming. Despite advancements in artificial intelligence (AI) for bioactivity prediction, challenges remain due to limited data availability and the interpretability issues in deep learning models, often leading to less-than-ideal predictions. To address these challenges, we developed PepExplainer, an explainable graph neural network based on substructure mask explanation (SME). This model excels at deciphering amino acid substructures, translating macrocyclic peptides into detailed molecular graphs at the atomic level, and efficiently handling non-canonical amino acids and complex macrocyclic peptide structures. PepExplainer's effectiveness is enhanced by utilizing the correlation between peptide enrichment data from selection-based focused library and bioactivity data, and employing transfer learning to improve bioactivity predictions of macrocyclic peptides against IL-17C/IL-17 RE interaction. Additionally, PepExplainer underwent further validation for bioactivity prediction using an additional set of thirteen newly synthesized macrocyclic peptides. Moreover, it enabled the optimization of the IC of a macrocyclic peptide, reducing it from 15 nM to 5.6 nM based on the contribution score provided by PepExplainer. This achievement underscores PepExplainer's skill in deciphering complex molecular patterns, highlighting its potential to accelerate the discovery and optimization of macrocyclic peptides.

Authors

  • Silong Zhai
    School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
  • Yahong Tan
    State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China.
  • Cheng Zhu
    Translational Sciences, Sanofi US, Framingham, MA, 01701, USA. Cheng.Zhu@sanofi.com.
  • Chengyun Zhang
    Artificial Intelligent Aided Drug Discovery Lab, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
  • Yan Gao
    Department of Rehabilitation Medicine, The First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
  • Qingyi Mao
    School of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China.
  • Youming Zhang
    Helmholtz International Lab for Anti-Infectives, Shandong University-Helmholtz Institute of Biotechnology, State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong 266237, PR China.
  • Hongliang Duan
    Artificial Intelligent Aided Drug Discovery Lab, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
  • Yizhen Yin
    State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China.